Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Bone Marrow Transplantation volume 44, pages 205–211 (2009)Cite this article

Abstract

The irradiation of cellular blood components to prevent transfusion-associated (TA)-GVHD is an established practice in the developed world. Susceptible patients include those who are immunosuppressed, fetuses, very premature neonates and patients who have an increased likelihood of possessing one HLA haplotype for which the blood component donor is homozygous. Problems and challenges associated with blood component irradiation include transfusion delay, cost, failure to irradiate when indicated, increased potassium accumulation in and decreased shelf life of RBC units, reduced RBC recovery and, in the United States, substantial and onerous security requirements for cesium-137 source irradiators and their operators. Microbial contamination of blood components can pose life-threatening risks for transfusion recipients. Donor history screening and infectious disease testing are a reactive response and expensive, as well as an imperfect and incomplete means for preventing these infectious risks. In response to these threats, pathogen reduction technologies have been developed. Two such innovations (INTERCEPT, Cerus Corporation, Concord, CA, USA; and Mirasol, CaridianBCT Biotechnologies, Lakewood, CO, USA) are approved for clinical use in many countries, though not in the United States. These processes have been shown to effectively prevent proliferation of nucleic acid-containing microbes, thereby providing broad protection against transfusion-transmitted infection. These technologies have also been shown to prevent the replication of WBC. In this report, we review the substantial in vitro, clinical trial and clinical practice observational evidence that non-irradiated INTERCEPT- and Mirasol-treated cellular blood components do not cause TA-GVHD. Implementation of these processes precludes the necessity for irradiating cellular blood components to prevent TA-GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Shimoda T . The case report of post-operative erythroderma. Geka 1955; 17: 487.

    Google Scholar 

  2. Hathaway W, Githens J, Blackburn W . Aplastic anemia, histocytosis and erythroderma in immunologically deficient children. N Engl J Med 1965; 273: 953–958.

    Article  CAS  Google Scholar 

  3. Szaley F, Buki B, Kalouics I, Keleman E . Post-transfusion GVHR in an adult with acute leukemia and aplastic anemia. Orv Hetil 1972; 113: 1275–1280.

    Google Scholar 

  4. Rosen R, Heustis D, Corrigan Jr J . Acute leukemia and granulocyte transfusion: fatal graft versus host reaction following transfusion of cells obtained from normal donors. J Pediatr 1978; 83: 268–270.

    Article  Google Scholar 

  5. Lowenthal R, Menon C, Challis D . Graft-versus-host-disease in consecutive patients with acute myeloid leukemia treated with blood cells from normal donors. Aust NZ J Med 1981; 11: 179–183.

    Article  CAS  Google Scholar 

  6. Postmus P, Mulholland J, Elema J . Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow: a report of 4 cases following ablative chemotherapy for solid tumors. Eur J Cancer Clin Oncol 1988; 24: 889–894.

    Article  CAS  Google Scholar 

  7. Thaler M, Shamiss A, Orgad S . The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 1989; 321: 25–28.

    Article  CAS  Google Scholar 

  8. Whitaker BI, Green J, King MR, Leibeg LL, Schlumpf KS, Schriber GB . The 2007 National Blood Collection and Utilization Survey Report. Department of Health and Human Services: Washington, DC, 2007, p 28.

    Google Scholar 

  9. NRC: SECY-08-0184. Strategy for the Security and Use of Cesium-137 Chloride Sources 2008. (http://www.nrc.gov/reading-rm/doc-collections/commission/secys/2008/secy2008-0184/2008-0184scy.html; accessed on 9 January 2009).

  10. America's Blood Centers Newsletter 12 December 2008: p 10.

  11. Briz M, Cabrera R, Sanjuan I, Fores R, Diez JL, Herrero M et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 409–411.

    Article  CAS  Google Scholar 

  12. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI . Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999; 39: 128–134.

    Article  CAS  Google Scholar 

  13. Petrides M, AuBuchon JP . To transfuse or not to transfuse: an assessment of risks and benefits. In: Mintz PD (ed). Transfusion Therapy: Clinical Principles and Practice, 2nd edn. AABB Press: Bethesda, MD, 2005, pp 657–690.

    Google Scholar 

  14. Leiby DA, Nguyen ML, Notari EP . Impact of donor deferrals for malaria on blood availability in the United States. Transfusion 2008; 48: 2222–2228.

    Article  Google Scholar 

  15. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534–1541.

    Article  CAS  Google Scholar 

  16. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496–1504.

    Article  CAS  Google Scholar 

  17. Alter HJ . Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22: 97–102.

    Article  Google Scholar 

  18. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP . Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133–153.

    Article  Google Scholar 

  19. Prowse C . Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124–133.

    Article  Google Scholar 

  20. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM et al. Proceedings of a consensus conference: pathogen inactivation—making decisions about new technologies. Transfus Med Rev 2008; 22: 1–34.

    Article  Google Scholar 

  21. Roback JD, Hossain MS, Lezhava L, Gorechlad JW, Alexander SA, Jaye DL et al. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 2003; 171: 6023–6031.

    Article  CAS  Google Scholar 

  22. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91: 2180–2188.

    CAS  PubMed  Google Scholar 

  23. Palszynski MM, Moroff G, Luban NL, Taylor BJ, Quinones RR . Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683–1689.

    Google Scholar 

  24. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140–3147.

    CAS  PubMed  Google Scholar 

  25. Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE . Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163: 5145–5156.

    CAS  PubMed  Google Scholar 

  26. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426–2433.

    Article  CAS  Google Scholar 

  27. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753–3760.

    Article  CAS  Google Scholar 

  28. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693–1704.

    Article  CAS  Google Scholar 

  29. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362–1372.

    Article  Google Scholar 

  30. Conlan M, Lin JS, Flament J, Lin L, Corash L . INTERCEPT platelets treated with Helinx technology to inactivate T-cells prevented transfusion-associated graft-versus-host disease (TV-GVHD): results of 3 clinical trials. VIII European Congress of the International Society of Blood Transfusion 2003. Istanbul, Turkey, pp 22.

  31. Cazenave JP, Waller C, Mendel I, Kientz D, Raidot JP, Wiesel ML et al. Impact of photochemical treatment of platelet components (INTERCEPT) on platelet and RBC component use by hematology-oncology patients during routine practice. Transfusion 2008; 48 (S2): 36A (abstract no. S95-030L).

    Google Scholar 

  32. Osselaer JC, Doyen C, Graux C, Chatelain C, Sonnet A, Jacquet M et al. Prevention of transfusion-associated graft versus host disease (TA-GVHD) by photochemical treatment of platelet components: clinical experience in routine use. ASH Annu Meet Abstr 2007; 110: 2885.

    Google Scholar 

  33. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061–1071.

    Article  Google Scholar 

  34. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315–323.

    Article  CAS  Google Scholar 

  35. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15–21.

    Article  CAS  Google Scholar 

  36. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174–1182.

    Article  CAS  Google Scholar 

  37. Fast LD, Dileone G, Li J, Goodrich RP . Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642–648.

    Article  CAS  Google Scholar 

  38. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich RP . Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2−/−gamma c−/− double knockout mice. Transfusion 2006; 46: 1553–1560.

    Article  CAS  Google Scholar 

  39. Fast LD, Marschner S, DiLeone G, Doane S, Fitzpatrick C, Goodrich RP . Functional inactivation of human white blood cells in whole blood products using the Mirasol system for whole blood. Transfusion 2008; 48 (S2): 169A–170A (abstract no. SP363).

    Google Scholar 

  40. Doane S, Reddy H, Fitzpatrick C, Keil S, Goodrich RP . Evaluation of pathogen reduction in whole blood with the Mirasol system for whole blood. Transfusion 2008; 48 (S2): 99A (abstract no. SP144).

    Google Scholar 

  41. Goodrich RP, Roberts T, Folléa G . Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008; 48 (S2): 20A (abstract no. S49-020G).

    Google Scholar 

  42. de Cock P, Vaquero M, Garcia R, Marceno R, Fusco GD, Freitas A et al. The Mirasol evaluation program: use of Mirasol pathogen reduction technology for platelets in routine clinical practice. Transfusion 2008; 48 (S2): 165A–166A (abstract no. SP351).

    Google Scholar 

Download references

Acknowledgements

The authors acknowledge the outstanding administrative support of Mrs Frances Parsons.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA

    P D Mintz & G Wehrli

  2. Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA

    P D Mintz

Authors
  1. P D Mintz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Wehrli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P D Mintz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mintz, P., Wehrli, G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 44, 205–211 (2009). https://doi.org/10.1038/bmt.2009.124

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.124

Keywords

Search

Advanced search

Quick links